Litcius/Paper detail

Bevacizumab plus erlotinib in Chinese patients with untreated, EGFR-mutated, advanced NSCLC (ARTEMIS-CTONG1509): A multicenter phase 3 study

Qing Zhou, Chong‐Rui Xu, Ying Cheng, Yunpeng Liu, Gongyan Chen, Jiuwei Cui, Nong Yang, Yong Song, Xiaoling Li, Shun Lü, Jianying Zhou, Zhiyong Ma, Shiying Yu, Cheng Huang, Yongqian Shu, Zhen Wang, Jin‐Ji Yang, Hai‐Yan Tu, Wen‐Zhao Zhong, Yi‐Long Wu

2021Cancer Cell228 citationsDOI

Topics & Concepts

ErlotinibBevacizumabMedicineInternal medicineLung cancerOncologyHazard ratioEpidermal growth factor receptorRegimenPhases of clinical researchErlotinib HydrochlorideCancerConfidence intervalChemotherapyLung Cancer Treatments and MutationsColorectal Cancer Treatments and StudiesPeptidase Inhibition and Analysis